Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 3/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | ANPEP | P15144 | 1/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.44 |
| ▸ | MMP8 | P22894 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | MME | P08473 | 2/20 | 0.44 |
| ▸ | ACE | P12821 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | REN | P00797 | 1/20 | 0.42 |
| ▸ | FNTA | P49354 | 1/20 | 0.41 |
| ▸ | FNTB | P49356 | 1/20 | 0.41 |
| ▸ | PGGT1B | P53609 | 1/20 | 0.41 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Levacetylleucine SCHEMBL6671878 | 0.91 | LTA4H (0.52) | PSMB5LTA4HANPEPMMP2MMP9 | |
| SCHEMBL2295176 | 0.91 | PSMB5 (0.47) | PSMB5ANPEPMMP2MMP9MMP8 | |
| Hydrochloric Acid SCHEMBL2297582 | 0.90 | PSMB5 (0.47) | PSMB5ANPEPMMP2MMP9MMP8 | |
| Alanine SCHEMBL671385 | 0.88 | PSMB5 (0.46) | PSMB5ANPEPMMP2MMP9MMP8 | |
| Leucine SCHEMBL27471555 | 0.81 | MAPT (0.47) | PSMB5ANPEPALDH1A1MMEACE | |
| SCHEMBL19605955 | 0.81 | MME (0.58) | PSMB5ANPEPMMP2MMP9MMP8 | |
| Leucine SCHEMBL6672109 | 0.80 | MAPT (0.50) | ANPEPALDH1A1MMEACECPA1 | |
| Leucine SCHEMBL27470583 | 0.80 | MAPT (0.50) | ANPEPALDH1A1MMEACECPA1 | |
| SCHEMBL10772819 | 0.77 | MMP2 (0.61) | PSMB5ANPEPMMP2MMP9MMP8 | |
| SCHEMBL2761181 | 0.76 | MME (0.63) | MMP2MMP9MMP8MMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1123412-B1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARM INC (US) | 2004-10-06 | — | — | EP | claimed |
| US-6613541-B1 | Pharmacology; bioassay; proteolysis; enzyme inhibitors; use to provide guidance for selecting dose amount and dose frequency of proteasome inhibitors for treatment of cancer, inflammatory and autoimmune diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | claimed |
| US-6465433-B1 | SUCH AS N-(2-PYRIDINE)CARBONYL-L-PHENYLALANINE-L-LEUCINE BORONIC ACID; PROTEASOME INHIBITORS; REDUCING RATE OF MUSCLE PROTEIN DEGRADATION | MILLENNIUM PHARMACEUTICALS, INC. | 2002-10-15 | — | — | US | claimed |
| US-6297217-B1 | TREATMENT OF CANCER WITH PROTEASE INHIBITORS | MILLENNIUM PHARMACEUTICALS, INC. | 2001-10-02 | — | — | US | claimed |
| EP-1123412-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | Millennium Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | claimed |
| US-6066730-A | Boronic ester and acid compounds, synthesis and uses | PROSCRIPT, INC. | 2000-05-23 | — | — | US | claimed |
| WO-2000023614-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | claimed |
| EP-1123412-B1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARM INC (US) | 2004-10-06 | — | — | EP | disclosed |
| US-6613541-B1 | Pharmacology; bioassay; proteolysis; enzyme inhibitors; use to provide guidance for selecting dose amount and dose frequency of proteasome inhibitors for treatment of cancer, inflammatory and autoimmune diseases | MILLENNIUM PHARMACEUTICALS, INC. | 2003-09-02 | — | — | US | disclosed |
| US-20010051654-A1 | Treatment of inflammatory and autoimmune diseases | ELLIOTT PETER J (US) | 2001-12-13 | — | — | US | disclosed |
| EP-1123412-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | Millennium Pharmaceuticals, Inc. (US) | 2001-08-16 | — | — | EP | disclosed |
| WO-2000023614-A1 | METHOD FOR MONITORING PROTEASOME INHIBITOR DRUG ACTION | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051654-A1 | Treatment of inflammatory and autoimmune diseases | NFKBIA, IKBKG, PSMB1 | PSMB5 4/4885LTA4H 613/4885ANPEP 2353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.